Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Jascayd Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedQualChoicePolicy CP.PHAR.759

    Clinical Policy: Nerandomilast (Jascayd)

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.759 alerts

    Get alerted when Policy CP.PHAR.759 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Jascayd in adult members with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis. It applies to QualChoice commercial, HIM/ICHRA, and Medicaid lines of business.

    Policy Summary
    PayerQualChoice
    PolicyNerandomilast (Jascayd) coverage
    Policy CodePolicy CP.PHAR.759
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that all applicable initial or continued therapy criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Progressive pulmonary fibrosis was added as a newly FDA-approved indication.

    Step-therapy requirements were revised for IPF and PPF.

    A rheumatologist was added as an eligible prescriber or consultant for PPF.

    The health-plan-approved quantity-limit criterion was removed.

    The HIM/ICHRA line of business was added.

    2FDA-approved covered indications
    18 mg BIDStandard dosage
    36 mg/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum daily dose
    12 monthsApproval duration

    Coverage Criteria

    Initial Therapy — Idiopathic Pulmonary Fibrosis

    Covered for IPF when ALL of the following are met.

    IPF initial therapy

    • Diagnosis and clinical eligibility

      • IPF diagnosis

        • Qualifying HRCT and confirmation

          • UIP pattern

            • Pulmonary fibrosis is shown on HRCT with a usual interstitial pneumonia (UIP) pattern.
          • Probable or indeterminate UIP pattern

            • HRCT shows a probable or indeterminate UIP pattern, and surgical lung biopsy, cellular analysis of bronchoalveolar lavage fluid, or transbronchial lung cryobiopsy confirms IPF.
      • Known causes of pulmonary fibrosis have been ruled out.
    • The medication is prescribed by or in consultation with a pulmonologist.
    • The member is at least 18 years old.≥ 18 years
    • Baseline FVC is at least 45% of predicted.FVC ≥ 45% of predicted
    • Baseline DLCO is at least 25% of predicted.DLCO ≥ 25% of predicted
    • Conditional IPF step therapy

      • Baseline FVC is less than 50% of predicted or baseline DLCO is less than 30% of predicted; the conditional step-therapy threshold is not met.
      • Required failures or exceptions

        • When baseline FVC is at least 50% and DLCO is at least 30%, both generic pirfenidone and generic nintedanib have failed at up to maximally indicated doses, unless clinically significant adverse effects were experienced or both drugs are contraindicated.FVC ≥ 50% and DLCO ≥ 30%
    • The dose does not exceed 36 mg per day or 2 tablets per day.Maximum 36 mg/day and 2 tablets/day

    Initial Therapy — Progressive Pulmonary Fibrosis

    Covered for PPF when ALL of the following are met.

    PPF initial therapy

    • Eligible underlying ILD

      • The member has idiopathic interstitial pneumonia manifesting PPF.
      • The member has autoimmune ILD manifesting PPF, such as rheumatoid arthritis-related ILD, mixed connective tissue disease-associated ILD, or systemic sclerosis-associated ILD.
      • The member has environmental- or occupational-exposure-related ILD manifesting PPF, such as hypersensitivity pneumonitis.
      • The member has sarcoidosis manifesting PPF.
    • The medication is prescribed by or in consultation with a pulmonologist or rheumatologist.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation of efficacy and safety supports review under the applicable off-label use policy or evidence of coverage documents.

    Clinical Thresholds

    Age
    Minimum age≥ 18 years
    IPF applicationRequired for initial therapy for idiopathic pulmonary fibrosis
    PPF applicationRequired for initial therapy for progressive pulmonary fibrosis
    Baseline FVC
    Minimum baseline FVC≥ 45% of predicted
    IPF useRequired as part of the baseline pulmonary-function criteria
    PPF useRequired as part of the baseline pulmonary-function criteria

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit documentation showing that all applicable initial or continued therapy criteria are met. Approved therapy is limited to a 12-month duration.

    • Initial approval criteria apply to idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF), as applicable.
    • Continued therapy requires eligibility under the continuation criteria and positive response to therapy.
    Step Therapy

    IPF Prerequisite Therapy

    For IPF, document failure of both generic pirfenidone and generic nintedanib at up to maximally indicated doses when baseline FVC is at least 50% and DLCO is at least 30%. The step-therapy requirement does not apply to Illinois HIM requests under IL HB 5395.

    • The requirement may be waived when clinically significant adverse effects are experienced or both therapies are contraindicated.

    Drug and Disease Overview

    Nerandomilast (Jascayd) is a phosphodiesterase 4 inhibitor indicated for adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). For IPF, coverage is based on pulmonary fibrosis demonstrated by HRCT, including a usual interstitial pneumonia pattern or selected probable or indeterminate UIP presentations requiring confirmatory testing. For PPF, coverage applies to specified interstitial lung diseases with objective progression documented by HRCT, decline in FVC, worsening respiratory symptoms, or increased fibrosis.

    Clinical Abbreviations

    DLCO
    Full termCarbon monoxide diffusing capacity
    Clinical rolePulmonary function measure used in the coverage criteria
    Coverage thresholdsBaseline DLCO ≥ 25% of predicted; PPF step therapy applies when baseline DLCO ≥ 30%
    FVC
    Full termForced vital capacity
    Clinical rolePulmonary function measure used in the coverage criteria and in assessing progression
    Coverage thresholdsBaseline FVC ≥ 45% of predicted; PPF progression may require a relative decline of ≥ 10%, or 5% to < 10% with worsening symptoms or increased HRCT fibrosis

    Initial Therapy Decision Paths

    Initial Therapy — IPF

    Initial IPF treatment requires ALL of the following criteria.

    IPF initial therapy

    • The member has a diagnosis of idiopathic pulmonary fibrosis.
    • The medication is prescribed by or in consultation with a pulmonologist.
    • The member is at least 18 years old.≥ 18 years
    • Diagnostic requirements

      • Qualifying HRCT and confirmation

    Continued Therapy

    Prerequisite Therapy

    StepApplicabilityRequired prior therapyException
    1IPF with baseline FVC ≥ 50% and DLCO ≥ 30%Failure of both generic pirfenidone and generic nintedanib at up to maximally indicated dosesRequirement does not apply if clinically significant adverse effects are experienced or both drugs are contraindicated; Illinois HIM requests are exempt under IL HB 5395
    StepApplicabilityRequired prior therapyException
    1PPF with baseline DLCO ≥ 30%Failure of generic nintedanib at up to maximally indicated dosesRequirement does not apply if nintedanib is contraindicated or clinically significant adverse effects are experienced; Illinois HIM requests are exempt under IL HB 5395

    Dose and Quantity Limits

    Nerandomilast (Jascayd)
    Maximum daily dose36 mg per day
    Maximum quantity2 tablets per day
    ApplicabilityThe dose must not exceed both limits for IPF or PPF therapy; dose increases during continued therapy must also remain within these limits
    Policy Summary
    PayerQualChoice
    PolicyNerandomilast (Jascayd) coverage
    Policy CodePolicy CP.PHAR.759
    Change TypeModified
    Effective DateJan 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation showing that all applicable initial or continued therapy criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation RequirementsDrug and Disease OverviewClinical AbbreviationsInitial Therapy Decision PathsContinued TherapyPrerequisite TherapyDose and Quantity Limits
  1. The member is at least 18 years old.≥ 18 years
  2. New-start progression and HRCT criteria

    • The request is not for a new start; the progression and HRCT requirements do not apply.
    • New-start requirements within the past 24 months

      • HRCT shows pulmonary fibrosis affecting more than 10% of lung volume.> 10% of lung volume
      • Qualifying FVC progression

        • There is a relative decline in FVC of at least 10% of the predicted value.Relative FVC decline ≥ 10% of predicted
        • There is a relative FVC decline of 5% to less than 10% of the predicted value plus worsening respiratory symptoms or an increased extent of fibrosis on HRCT.Relative FVC decline 5% to < 10% plus symptoms or increased fibrosis on HRCT
  3. Baseline FVC is at least 45% of predicted.FVC ≥ 45% of predicted
  4. Baseline DLCO is at least 25% of predicted.DLCO ≥ 25% of predicted
  5. Conditional PPF step therapy

    • Baseline DLCO is less than 30% of predicted; the conditional step-therapy threshold is not met.
    • When baseline DLCO is at least 30%, generic nintedanib has failed at up to maximally indicated doses, unless it is contraindicated or clinically significant adverse effects were experienced.DLCO ≥ 30%
  6. The dose does not exceed 36 mg per day or 2 tablets per day.Maximum 36 mg/day and 2 tablets/day
  7. Baseline DLCO
    Minimum baseline DLCO≥ 25% of predicted
    IPF useRequired as part of the baseline pulmonary-function criteria
    PPF useRequired as part of the baseline pulmonary-function criteria
    IPF Step-Therapy Threshold
    Applies whenBaseline FVC ≥ 50% and DLCO ≥ 30%
    Required prior therapiesGeneric pirfenidone and generic nintedanib
    Failure standardFailure at up to maximally indicated doses, unless clinically significant adverse effects occur or both drugs are contraindicated
    PPF Step-Therapy Threshold
    Applies whenBaseline DLCO ≥ 30%
    Required prior therapyGeneric nintedanib
    Failure standardFailure at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects occur
    PPF HRCT Fibrosis Extent
    Required fibrosis extent> 10% of lung volume
    Assessment methodPulmonary fibrosis is evaluated on HRCT
    TimingRequirement applies to new starts and must be documented within the past 24 months
    PPF FVC Progression
    Primary qualifying declineRelative FVC decline ≥ 10% of the predicted value
    Alternative declineRelative FVC decline of 5% to < 10% of the predicted value
    Additional finding for alternative declineWorsening respiratory symptoms or an increased extent of fibrosis on HRCT
    TimingProgression must be documented within the past 24 months for new starts
    Step Therapy

    PPF Prerequisite Therapy

    For PPF, document failure of generic nintedanib at up to maximally indicated doses when baseline DLCO is at least 30%. The step-therapy requirement does not apply to Illinois HIM requests under IL HB 5395.

    • The requirement may be waived when generic nintedanib is contraindicated or clinically significant adverse effects are experienced.
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation supporting that the member has met all applicable approval criteria.

    • Acceptable supporting information includes office chart notes, laboratory results, pulmonary testing, imaging reports, and other relevant clinical records.
    Documentation Required

    IPF Supporting Records

    For IPF requests, submit records documenting the diagnosis and the member’s age, specialist involvement, pulmonary testing, HRCT findings, and exclusion of known causes of pulmonary fibrosis.

    • Diagnosis of IPF and prescription by or consultation with a pulmonologist.
    • Member is at least 18 years old.
    • HRCT shows pulmonary fibrosis with a UIP pattern, or a probable/indeterminate UIP pattern confirmed as IPF by surgical lung biopsy, cellular analysis of bronchoalveolar lavage fluid, or transbronchial lung cryobiopsy.
    • Known causes of pulmonary fibrosis have been ruled out.
    • Baseline FVC is at least 45% of predicted and baseline DLCO is at least 25% of predicted.
    Documentation Required

    PPF Supporting Records

    For PPF requests, submit records documenting the underlying ILD, specialist involvement, the member’s age, HRCT findings, FVC progression, and related symptoms or imaging progression when applicable.

    • Underlying ILD is idiopathic interstitial pneumonia, autoimmune ILD, environmental or occupational exposure-related ILD, or sarcoidosis manifesting PPF.
    • Prescription is by or in consultation with a pulmonologist or rheumatologist; member is at least 18 years old.
    • For new starts, within the past 24 months HRCT shows pulmonary fibrosis affecting more than 10% of lung volume.
    • For new starts, document either a relative FVC decline of at least 10% of predicted, or a relative FVC decline of 5% to less than 10% plus worsening respiratory symptoms or increased fibrosis on HRCT.
    • Baseline FVC is at least 45% of predicted and baseline DLCO is at least 25% of predicted.
    Denial Risk

    Failure to Meet Approval Criteria

    Requests may be denied when the applicable indication-specific requirements are not met or when required prerequisite therapy, clinical findings, testing, or continuation criteria are not documented.

    • IPF requests must satisfy all applicable diagnosis, specialist, age, HRCT, exclusion, FVC, DLCO, prerequisite-therapy, and dosing requirements.
    • PPF requests must satisfy all applicable underlying-ILD, specialist, age, HRCT, progression, FVC, DLCO, prerequisite-therapy, and dosing requirements.
    • Continued therapy requires qualifying prior or current coverage status, positive response to therapy, and compliance with the dose limit for any dose increase.
    Denial Risk

    Noncovered Indications

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation of efficacy and safety is provided under the applicable off-label use policy or evidence of coverage documents.

    • Applicable references include CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.
    Denial Risk

    Dose Exceeds Policy Maximum

    Do not submit a request exceeding the policy maximum dose of 36 mg per day or 2 tablets per day.

    • The limit applies to initial approval for IPF and PPF.
    • For continued therapy, any dose increase must remain at or below both 36 mg per day and 2 tablets per day.
    HRCT
    Full termHigh-resolution computed tomography
    Clinical roleImaging used to evaluate pulmonary fibrosis and its extent
    Coverage useEvaluates UIP patterns for IPF and fibrosis affecting > 10% of lung volume for new-start PPF criteria
    IPF
    Full termIdiopathic pulmonary fibrosis
    Coverage statusFDA-approved covered indication for nerandomilast
    Diagnostic associationIPF coverage requires pulmonary fibrosis on HRCT with a UIP pattern, or a probable or indeterminate UIP pattern with confirmatory testing
    PPF
    Full termProgressive pulmonary fibrosis
    Coverage statusFDA-approved covered indication for nerandomilast
    Progression basisFor new starts, requires HRCT fibrosis affecting > 10% of lung volume plus qualifying FVC decline, worsening respiratory symptoms, or increased fibrosis on HRCT
    UIP
    Full termUsual interstitial pneumonia
    Clinical descriptionRadiologic pattern identified on HRCT
    Association with IPFA UIP pattern supports the IPF diagnostic criterion; probable or indeterminate UIP requires confirmatory testing
    HRCT shows a UIP pattern.
  8. HRCT shows a probable or indeterminate UIP pattern, with IPF confirmed by surgical lung biopsy, cellular analysis of bronchoalveolar lavage fluid, or transbronchial lung cryobiopsy.
  9. Known causes of pulmonary fibrosis have been ruled out.
  10. Baseline FVC is at least 45% of predicted.FVC ≥ 45% of predicted
  11. Baseline DLCO is at least 25% of predicted.DLCO ≥ 25% of predicted
  12. Conditional step therapy

    • Baseline FVC is less than 50% of predicted or baseline DLCO is less than 30% of predicted.
    • When baseline FVC is at least 50% and DLCO is at least 30%, both generic pirfenidone and generic nintedanib have failed at up to maximally indicated doses, unless clinically significant adverse effects occurred or both are contraindicated.FVC ≥ 50% and DLCO ≥ 30%
  13. The dose does not exceed 36 mg per day or 2 tablets per day.Maximum 36 mg/day and 2 tablets/day
  14. Initial Therapy — PPF

    Initial PPF treatment requires ALL of the following criteria.

    PPF initial therapy

    • Eligible underlying ILD

      • Idiopathic interstitial pneumonia manifesting PPF.
      • Autoimmune ILD manifesting PPF, including rheumatoid arthritis-related ILD, mixed connective tissue disease-associated ILD, or systemic sclerosis-associated ILD.
      • Environmental- or occupational-exposure-related ILD manifesting PPF, including hypersensitivity pneumonitis.
      • Sarcoidosis manifesting PPF.
    • The medication is prescribed by or in consultation with a pulmonologist or rheumatologist.
    • The member is at least 18 years old.≥ 18 years
    • New-start progression and HRCT requirements

      • The request is not for a new start.
      • For a new start, within the past 24 months HRCT shows pulmonary fibrosis affecting more than 10% of lung volume and there is either a relative FVC decline of at least 10% of predicted or a relative FVC decline of 5% to less than 10% plus worsening respiratory symptoms or increased fibrosis on HRCT.> 10% lung-volume fibrosis; FVC decline ≥ 10%, or 5% to < 10% plus symptoms or increased fibrosis
    • Baseline FVC is at least 45% of predicted.FVC ≥ 45% of predicted
    • Baseline DLCO is at least 25% of predicted.DLCO ≥ 25% of predicted
    • Conditional step therapy

      • Baseline DLCO is less than 30% of predicted.
      • When baseline DLCO is at least 30%, generic nintedanib has failed at up to maximally indicated doses, unless it is contraindicated or clinically significant adverse effects occurred.DLCO ≥ 30%
    • The dose does not exceed 36 mg per day or 2 tablets per day.Maximum 36 mg/day and 2 tablets/day